14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $84.70 $93.35 Wednesday, 24th Apr 2024 BMRN stock ended at $91.20. This is 0.93% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 2.20% from a day low at $91.01 to a day high of $93.02.
90 days $83.44 $94.15
52 weeks $76.02 $99.55

Historical BioMarin Pharmaceutical Inc. prices

Date Open High Low Close Volume
Mar 21, 2023 $92.24 $92.82 $91.77 $92.08 1 581 097
Mar 20, 2023 $92.07 $93.76 $91.23 $92.34 1 201 310
Mar 17, 2023 $92.37 $92.45 $90.49 $91.67 1 757 429
Mar 16, 2023 $87.45 $93.63 $87.34 $93.41 2 829 181
Mar 15, 2023 $89.25 $89.64 $87.52 $87.74 1 512 192
Mar 14, 2023 $91.47 $91.57 $89.96 $90.25 1 556 408
Mar 13, 2023 $90.45 $92.64 $89.83 $90.02 1 956 749
Mar 10, 2023 $92.28 $92.91 $89.39 $90.49 1 692 374
Mar 09, 2023 $94.13 $94.61 $92.17 $92.99 1 519 123
Mar 08, 2023 $93.53 $94.60 $92.81 $94.31 1 582 356
Mar 07, 2023 $93.47 $95.50 $92.88 $93.42 2 360 066
Mar 06, 2023 $94.99 $97.11 $93.38 $94.30 4 400 580
Mar 03, 2023 $100.26 $101.48 $98.65 $101.20 1 340 403
Mar 02, 2023 $100.39 $100.79 $99.25 $100.12 1 170 896
Mar 01, 2023 $100.26 $102.79 $100.26 $100.99 1 689 053
Feb 28, 2023 $99.30 $102.96 $97.37 $99.59 2 826 704
Feb 27, 2023 $102.31 $103.58 $102.09 $103.24 1 427 064
Feb 24, 2023 $102.50 $102.96 $101.48 $102.07 1 467 928
Feb 23, 2023 $103.20 $103.98 $102.78 $103.18 979 799
Feb 22, 2023 $104.37 $105.69 $102.94 $103.12 1 940 601
Feb 21, 2023 $108.44 $108.44 $105.92 $105.97 986 988
Feb 17, 2023 $107.04 $108.36 $106.55 $108.31 960 198
Feb 16, 2023 $108.06 $108.28 $106.76 $107.29 880 038
Feb 15, 2023 $108.60 $108.82 $107.66 $108.18 1 202 332
Feb 14, 2023 $108.00 $109.13 $105.93 $108.74 1 193 049
Click to get the best stock tips daily for free!

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical. BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o... BMRN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT